POR FESR 2014-2020, Asse I, Azione 3.4.1. – Avviso Large 2021 – Regione Umbria

Feb 21, 2023

“Farmaci, i Successi del Made in Italy” Tes Pharma in "Otto e Mezzo" of La7

Dec 2, 2022

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

Nov 8, 2022

X-ray Structure of Human ACMSD with TES-1025

Apr 8, 2022

Prof. Andrea Alimonti Visit Tes Pharma

Mar 18, 2022

Prof. Roberto Pellicciari Recipient of the EFMC Honorary Fellow Award.

Aug 18, 2021

POR FESR 2014-2020, Asse I, Azione 1.1.1. – Avviso Ricerca 2020 – Regione Umbria

Jul 15, 2021

POR FESR 2014-2020. Asse I Azione 1.1.1. – Avviso Ricerca 2018 – Regione Umbria

May 4, 2020

Mitochondrial Dysfunction is a Key Driver of Acute Kidney Injury Pathophysiology

Dec 18, 2018

Targeting NAD+ Synthesis via inhibition of ACMSD to prevent NAFLD and AKI

Nov 28, 2018

De novo NAD+ synthesis enhances mitochondrial function and improves health

Oct 25, 2018

POR FESR 2014-2020 Regione Umbria

Mar 22, 2018

α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Inhibitors as Novel Modulators of NAD+ Biosynthesis

Jan 29, 2018